As described in this review, interfering with signaling pathways like Myc and NF-κB as well as cellular metabolism showed promising effects in the diminishment of endometrial cancer stem cells and could therefore display considerable therapeutic targets for CSC-directed cancer therapy (Figure 2). The gene discussed is MYC; the disease is cancer.